Navigation Links
OriGene Technologies, Inc. to Build the World's Largest TrueMAB(TM) Monoclonal Antibody Facility in Wuxi, China
Date:5/18/2010

ROCKVILLE, Md., May 18 /PRNewswire/ -- OriGene Technologies, Inc. with the support of Wuxi Biopharmaceutical R&D Outsourcing Services Park (China), will build one of the largest and most sophisticated monoclonal antibody production centers in the world in Wuxi, China. The new, high-throughput production facility is expected to have over one thousand employees with the capacity to produce over 20,000 TrueMAB™ antibodies per year.

Monoclonal antibodies have become an invaluable tool for researchers to develop diagnostic and therapeutic applications. TrueMAB™ antibodies from OriGene are generated using OriGene's large collection of full-length human proteins as primary antigens that have been affinity purified under native conditions to preserve natural protein conformations. As a result, TrueMAB™ antibodies provide higher sensitivity and specificity for the recognition of native epitopes on the protein's natural conformational structures. With the introduction of OriGene's TrueMAB™ antibodies, OriGene now provides higher quality and greater numbers of monoclonal antibodies to the global research market place to address complex applications such as flow cytometry, ELISA, IHC, antibody arrays, Luminex assays and more.

To learn more about OriGene's genome-wide monoclonal antibody program and the TrueMAB™ collection, please visit www.origene.com/antibody/TrueMAB or contact James Hu at businessdev@origene.com.

About OriGene Technologies

OriGene Technologies, Inc., is a gene centric life sciences company dedicated to support academic, pharmaceutical and biotech companies in their research of gene functions and drug discovery. OriGene develops proteins, antibodies, and other molecular tools to allow researchers to analyze their data on a multiplex level. OriGene's novel product line includes the world's largest cDNA and shRNA clone collections, over 5,000 purified human proteins, high quality monoclonal antibodies (TrueMAB™), 100,000 highly validated human tissues, and protein microarray products and services. OriGene also provides a broad range of antibody validation products including genome-wide tagged antigen standards and extensive IHC slides derived from our tissue collection. For more information visit www.origene.com.


'/>"/>
SOURCE OriGene Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. OriGene Announces 37,000 ORF cDNA Clones in a GFP Vector
2. OriGene Technologies, Inc. Establishes High Throughput Monoclonal Antibody Production Outsourcing Center in China
3. OriGene Launches 5,000 Purified Human Proteins from HEK293 Cells
4. OriGene Technologies Acquires Marligen Biosciences
5. OriGene Technologies Raises $16 Million to Build the Largest Collection of Next Generation Monoclonal Antibodies (TrueMAB(TM)) to Cover the Majority of Human Proteome
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
8. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
9. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
10. Neurobiological Technologies, Inc. Reports Receipt of Notice From Nasdaq
11. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Infectex Ltd., a Russian portfolio company of Maxwell Biotech Venture Fund (MBVF), ... the standard drug therapy regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). SQ109 is ... ) and the US National Institutes of Health. ... ... ...
(Date:3/27/2017)... NC (PRWEB) , ... March 27, 2017 , ... ... Clinical Trial Collaborations (CTC) conference presented by The Conference Forum in Boston on ... way they collaborate to drive improved clinical trial outcomes and bring them closer to ...
(Date:3/27/2017)... 2017 Neurotrope, Inc. (OTCQB: NTRP),  a ... diseases, including Alzheimer,s disease, today announced that it ... the Company,s common stock on the NASDAQ Capital ... Market, a unit of the NASDAQ OMX Group. ... Opening Bell at the NASDAQ MarketSite in Times ...
(Date:3/24/2017)... Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: SVA), ... , today announced that its board of directors has amended its ... from March 27, 2017 to March 27, 2018. The amendment was not ... Biotech Ltd. ... Sinovac Biotech Ltd. is a China -based ...
Breaking Biology Technology:
(Date:3/2/2017)... Summary This report provides all ... and its partnering interests and activities since 2010. ... The Partnering Deals and Alliance since 2010 report provides ... of the world,s leading life sciences companies. ... ensure inclusion of the most up to date deal ...
(Date:2/28/2017)... , February 28, 2017 News solutions ... ... Amsterdam from 14 to 16 March, Materna will ... and show how seamless travel is a real benefit for passengers. ... added biometrics to their passenger touch point solutions to take passengers ...
(Date:2/22/2017)... 22, 2017 With the biometrics market ... identifies four technologies that innovative and agile startups ... share in the changing competitive landscape: multifactor authentication ...   "Companies can no longer afford ... says Dimitrios Pavlakis , Industry Analyst at ...
Breaking Biology News(10 mins):